CDX2 and goblet cell carcinoma: In 60 GCC cases, CDX2 expression was detectable in half of the cases 32/60 (53.3%), with 17/60 (18.3%) cases considered as CDX2-strong staining, and 15/60 (25.0%) cases considered as CDX2-weak staining (Figure 2A).